Welcome to the official website of ogina pharmaceutical! Information Hotline: 024-89892244

Information Center

Information Center

Master the real-time information, understand the industry information

Product Center

Product Center

Love the motherland, love innovation, love patients

Information Center

Information Center

Master the real-time information, understand the industry information

Product Center

Product Center

Love the motherland, love innovation, love patients

Technological Innovation

technological innovation

Adhere to scientific and technological innovation and create excellent brand

Service Zone

service sector

Your health my mission

The R & D team of Shenyang ogina Pharmaceutical Co., Ltd. is composed of several pharmaceutical professional researchers and overseas expert teams, with technical research and product development experience, and has established close technical cooperation relationship with many domestic pharmaceutical and chemical colleges. The company's marketing network all over the country, and has many years of drug marketing experience. Every time the National Drug Certification Center GMP certification, ogina pharmaceutical has passed high marks. With its excellent product quality, ogina pharmaceutical has won wide praise in the industry, won the respect of cooperative customers, and won the trust of consumers.

About Us

About us

Trust first, win win cooperation

Why why choose ogina

did you choose Original?

Aojina Pharmaceutical Co., Ltd. is subordinate to Shenyang ogina group. Mr. Wei Guoping, chairman of the group, is a doctor returned from France and was once a deputy to Liaoning Provincial People's Congress. Founded in 1999, the company is a pharmaceutical enterprise integrating R & D, production, sales and service. The main products include 100mg aspirin enteric coated tablets, bubble puff Tong (aspirin vitamin C effervescent tablets), bubble paracetamol (paracetamol and vitamin C effervescent tablets), etc. Among them, 100mg aspirin enteric coated tablets were approved by the State Food and Drug Administration for primary prevention of myocardial infarction on May 18, 2009. The product was put on the market in 2006. In January 2013, it was proved that it was bioequivalent to the original "baiaspiling" through a double-blind trial conducted by the clinical trial center of China Medical University, an authoritative clinical institution.

© two thousand and eighteen Shenyang Ogina Pharmaceutical Co., Ltd company copyright
Liaoicp no.18002084-1 (Liao) - non operating - 2020-0097 Technical support: yono Technology